T-knife Taps Into Investor Interest in T-Cell Receptor Therapies
Raises $110m In Series B
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.
You may also be interested in...
Sweden-based Anocca AB will use a just completed $47m Series B financing to advance its industrialized cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells Scrip.
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.
A mix of equity and debt financing has raised enough to satisfy Santhera's liquidity needs until mid-2022, which will be after the Swiss firm has filed its Duchenne drug vamorolone.